By Marie Rosenthal, MS
The FDA issued an emergency use authorization (EUA) for the investigational use of convalescent plasma for treatment of COVID-19 in hospitalized patients.
Despite encouraging early results, however, infectious disease specialists said more study in controlled trials is needed to ensure its effectiveness and to determine when this treatment should be given, which patients should receive it, the amount of antibodies the plasma should contain, and how long the immune response